Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing.
Lung cancer is the most common malignancy and the leading cause of cancer deaths worldwide. While smoking is by far the leading cause of lung cancer, other environmental and genetic factors influence the development and progression of the cancer. Since unique mutations patterns have been observed in individual cancer samples, identification and characterization of the distinctive lung cancer molecular profile is essential for developing more effective, tailored therapies. Until recently, personalized DNA sequencing to identify genetic mutations in cancer was impractical and expensive. The recent technological advancements in next-generation DNA sequencing, such as the semiconductor-based Ion Torrent sequencing platform, has made DNA sequencing cost and time effective with more reliable results. Using the Ion Torrent Ampliseq Cancer Panel, we sequenced 737 loci from 45 cancer-related genes to identify genetic mutations in 76 human lung cancer samples. The sequencing analysis revealed missense mutations in KRAS, EGFR, and TP53 genes in the breast cancer samples of various histologic types. Thus, this study demonstrates the necessity of sequencing individual human cancers in order to develop personalized drugs or combination therapies to effectively target individual, breast cancer-specific mutations.
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Xin
X
Cai
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Jianhui
J
Sheng
San Valley Biotechnology Incorporated, Beijing, China.
Chuanning
C
Tang
Norris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California Los Angeles, Los Angeles, California, United States of America.
Vijayalakshmi
V
Nandakumar
San Valley Biotechnology Incorporated, Beijing, China.
Hua
H
Ye
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Hong
H
Ji
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Haiying
H
Tang
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Yu
Y
Qin
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Hongwei
H
Guan
San Valley Biotechnology Incorporated, Beijing, China.
Feng
F
Lou
San Valley Biotechnology Incorporated, Beijing, China.
Dandan
D
Zhang
San Valley Biotechnology Incorporated, Beijing, China.
Hong
H
Sun
San Valley Biotechnology Incorporated, Beijing, China.
Haichao
H
Dong
San Valley Biotechnology Incorporated, Beijing, China.
Guangchun
G
Zhang
San Valley Biotechnology Incorporated, Beijing, China.
Zhiyuan
Z
Liu
San Valley Biotechnology Incorporated, Beijing, China.
Zhishou
Z
Dong
San Valley Biotechnology Incorporated, Beijing, China.
Baishuai
B
Guo
San Valley Biotechnology Incorporated, Beijing, China.
He
H
Yan
San Valley Biotechnology Incorporated, Beijing, China.
Chaowei
C
Yan
San Valley Biotechnology Incorporated, Beijing, China.
Lu
L
Wang
San Valley Biotechnology Incorporated, Beijing, China.
Ziyi
Z
Su
San Valley Biotechnology Incorporated, Beijing, China.
Yangyang
Y
Li
Norris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California Los Angeles, Los Angeles, California, United States of America.
Lindsey
L
Jones
Norris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California Los Angeles, Los Angeles, California, United States of America.
Xue F
XF
Huang
Norris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California Los Angeles, Los Angeles, California, United States of America.
Si-Yi
SY
Chen
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Taihua
T
Wu
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Hongli
H
Lin
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics; D004252:DNA Mutational Analysis / Q000379:methods; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D017422:Sequence Analysis, DNA / Q000379:methods*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*; D018631:ras Proteins / Q000235:genetics*
C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins